Aviva plc (AV) is a leading insurance—diversified business based in the UK. It opened the day at 292.7p after a previous close of 287.3p. During the day the price has varied from a low of 286.2p to a high of 292.7p. The latest price was 286.6p (25 minute delay). Aviva is listed on the London Stock Exchange (LSE) and employs 31,181 staff. All prices are listed in pence sterling.
Since the stock market crash in March caused by coronavirus, Aviva's share price has had significant negative movement.
Its last market close was 282.2p, which is 30.17% down on its pre-crash value of 404.1p and 37.19% up on the lowest point reached during the March crash when the shares fell as low as 205.7p.
If you had bought £1,000 worth of Aviva shares at the start of February 2020, those shares would have been worth £525.66 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth £703.04.
|52-week range||205.7p - 439.4p|
|50-day moving average||279.8743p|
|200-day moving average||270.7489p|
|Wall St. target price||551.33p|
|Dividend yield||0.06p (2.13%)|
|Earnings per share (TTM)||54.9p|
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
|1 week (2020-10-15)||2.76%|
|1 month (2020-09-25)||2.39%|
|3 months (2020-07-24)||1.99%|
|6 months (2020-04-24)||24.39%|
|1 year (2019-10-25)||-31.91%|
|2 years (2018-10-25)||-31.45%|
|3 years (2017-10-25)||-42.91%|
|5 years (2015-10-23)||-40.37%|
Valuing Aviva stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Aviva's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Aviva's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 5x. In other words, Aviva shares trade at around 5x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the FTSE 250 at the end of September 2019 (19.71). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
However, Aviva's P/E ratio is best considered in relation to those of others within the insurance—diversified industry or those of similar companies.
Aviva's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.8748. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Aviva's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
However, it's sensible to consider Aviva's PEG ratio in relation to those of similar companies.
Aviva's EBITDA (earnings before interest, taxes, depreciation and amortisation) is a whopping £3.7 billion.
The EBITDA is a measure of a Aviva's overall financial performance and is widely used to measure a its profitability.
To put Aviva's EBITDA into context you can compare it against that of similar companies.
|Revenue TTM||£37.2 billion|
|Operating margin TTM||9.1%|
|Gross profit TTM||£13.9 billion|
|Return on assets TTM||0.45%|
|Return on equity TTM||12.2%|
|Market capitalisation||£11.1 billion|
TTM: trailing 12 months
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Aviva.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Total ESG risk: 26.64
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Aviva's overall score of 26.64 (as at 10/01/2020) is pretty good – landing it in it in the 37th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Aviva is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
To gain some more context, you can compare Aviva's total ESG risk score against those of similar companies.
Environmental score: 4.45/100
Aviva's environmental score of 4.45 puts it squarely in the 5th percentile of companies rated in the same sector. This could suggest that Aviva is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Social score: 14.07/100
Aviva's social score of 14.07 puts it squarely in the 5th percentile of companies rated in the same sector. This could suggest that Aviva is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Governance score: 13.12/100
Aviva's governance score puts it squarely in the 5th percentile of companies rated in the same sector. That could suggest that Aviva is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Controversy score: 2/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. A high-profile company, Aviva scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that Aviva has, for the most part, managed to keep its nose clean.
Wondering how that compares? Below are the controversy scores of similar companies.
|Total ESG score||26.64|
|Total ESG percentile||37.04|
|Environmental score percentile||5|
|Social score percentile||5|
|Governance score percentile||5|
|Level of controversy||2|
Dividend payout ratio: 4981.82% of net profits
Recently Aviva has paid out, on average, around 4981.82% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 2.13% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Aviva shareholders could enjoy a 2.13% return on their shares, in the form of dividend payments. In Aviva's case, that would currently equate to about 0.06p per share.
Aviva's payout ratio would broadly be considered high, and as such this stock could appeal to those looking to generate an income. Bear in mind however that companies should normally also look to re-invest a decent amount of net profits to ensure future growth.
The latest dividend was paid out to all shareholders who bought their shares by 13 August 2020 (the "ex-dividend date").
Aviva's dividend payout ratio is perhaps best considered in relation to those of similar companies.
Aviva's shares were split on a 12:11 basis on 25 March 2009. So if you had owned 11 shares the day before before the split, the next day you'd have owned 12 shares. This wouldn't directly have changed the overall worth of your Aviva shares – just the quantity. However, indirectly, the new 8.3% lower share price could have impacted the market appetite for Aviva shares which in turn could have impacted Aviva's share price.
Over the last 12 months, Aviva's shares have ranged in value from as little as 205.7p up to 439.4p. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (LSE average) beta is 1, while Aviva's is 1.1028. This would suggest that Aviva's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
To put Aviva's beta into context you can compare it against those of similar companies.
Aviva plc provides various insurance and savings products primarily in the United Kingdom, rest of Europe, North America, and South-East Asia. The company offers life insurance, long term health and accident insurance, savings, pension, and annuity products, as well as pension fund business and lifetime mortgage products. It also provides insurance cover to individuals, small and medium-sized businesses for risks associated primarily with motor vehicles and medical expenses, as well as property and liability, such as employers' and professional indemnity liabilities. In addition, the company offers personal and commercial lines insurance products; long-term insurance and savings products, primarily for individuals. Further, it provides investment management services for institutional pension fund mandates; and manages various retail investment products, including investment funds, unit trusts, open-ended investment companies, and individual savings accounts for third-party financial institutions, pension funds, public sector organizations, investment professionals, and private investors. Additionally, the company offers asset management, retirement, and protection insurance products. The company markets its products through a network of insurance brokers, as well as MyAviva platform. The company was formerly known as CGNU plc and changed its name to Aviva plc in July 2002. Aviva plc was founded in 1696 and is headquartered in London, the United Kingdom.
Everything we know about the Virpax Pharmaceuticals IPO, plus information on how to buy it.
Everything we know about the Vivos Therapeutics IPO, plus information on how to buy it.
Everything we know about the Kiromic Biopharma IPO, plus information on how to buy it.
Everything we know about the Codiak BioSciences IPO, plus information on how to buy it.
Everything we know about the Triller IPO, plus information on how to buy it.
Everything we know about the Eastern Bank IPO, plus information on how to buy it.
Everything we know about the Wish IPO, plus information on how to buy it.
Everything we know about the MINISO Group Holding Limited IPO, plus information on how to buy it.
Everything we know about the Playboy IPO, plus information on how to buy it.
Everything we know about the iHuman IPO, plus information on how to buy it.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.